This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Placebo
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict OTHER HIGH
This is a structural / educational entry, not a compound recommendation. It exists to give Nootpedia readers a calibrated framework for interpreting EVERY OTHER compound entry on the wiki. The verdict is "REFERENCE-ENTRY" because (a) placebo is not a compound the user can purchase or self-experiment with as a primary intervention, (b) understanding placebo magnitude across endpoint types is essential for reading the evidence base of every nootropic, peptide, and supplement on this site, and (c) knowing where the placebo response is large (subjective pain, mood, sleep, fatigue) vs small (blood pressure, lab values, mortality) is the single most important calibration any biohacker can absorb. Confidence is HIGH because the placebo literature is one of the most-replicated bodies of evidence in clinical research — Hróbjartsson & Gøtzsche's Cochrane reviews, Wager's neuroimaging work, and Kaptchuk's open-label placebo program form a triangulated consensus.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
All profiles, all goals | T | is a REFERENCE-ENTRY. Read it once, internalize the framework, apply to every other entry on the wiki. The "decision" is conceptual: when you read a compound's evidence, ask what the placebo magnitude is for that endpoint, and whether the compound's claimed effect exceeds it. The categorical heuristic for every compound on Nootpedia: | Endpoint type | Placebo magnitude | What this means for you | |---|---|---| | Subjective pain (VAS, NRS) | LARGE (40-50% response rate, effect size 0.3-0.5) | Demand large effect sizes, blinded protocols, or objective correlates before believing a pain claim | | Mood (PHQ-9, HAM-D, BDI) | LARGE (30-50% in mild-mod depression) | Same — mild antidepressants barely beat placebo; the effect size on YOUR mood is meaningfully smaller than the marketing implies | | Sleep quality (subjective rating) | LARGE | Wearable objective sleep metrics (HRV, deep sleep min) are far harder to placebo | | Fatigue | LARGE | Especially in cancer-related, post-viral, chronic conditions | | Anxiety (subjective) | MODERATE-LARGE | Acute interventions show smaller placebo than chronic | | Sleep latency (objective, polysomnography) | SMALL | Real pharmacology shows up here; subjective sleep quality less so | | Cognitive task performance (Stroop, n-back, RT) | SMALL-MODERATE | Effects often disappear under blinding | | Resting HR, HRV | SMALL | Mostly placebo-immune in healthy subjects | | Blood pressure (objective, ambulatory) | SMALL | Placebo-immune in long-term studies | | Body weight, body composition | SMALL | Placebo-immune; demand DEXA or consistent scale data | | Lipid panel, HbA1c, fasting glucose | NEGLIGIBLE | Placebo-immune | | Hormone panels (testosterone, cortisol, IGF-1) | NEGLIGIBLE | Placebo-immune | | Athletic performance (time trials, 1RM) | SMALL-MODERATE | Caffeine-style ergogenic effects show up vs placebo cleanly | | Mortality, MI, stroke, cancer | ZERO | Placebo cannot save your life. Hard endpoints are placebo-immune. | The single most useful sentence in this entire entry: if a compound's only evidence is "users report" or "I feel sharper" without objective biomarker correlation or placebo-controlled blinded trial data, its effect is at most equal to the placebo magnitude for the relevant endpoint — and often is the placebo magnitude. That doesn't mean it's worthless (real benefit at the placebo magnitude is still real benefit), but it does mean the molecule is not the active ingredient. The ritual is the active ingredient. |
- All profiles, all goalsT
is a REFERENCE-ENTRY. Read it once, internalize the framework, apply to every other entry on the wiki. The "decision" is conceptual: when you read a compound's evidence, ask what the placebo magnitude is for that endpoint, and whether the compound's claimed effect exceeds it. The categorical heuristic for every compound on Nootpedia: | Endpoint type | Placebo magnitude | What this means for you | |---|---|---| | Subjective pain (VAS, NRS) | LARGE (40-50% response rate, effect size 0.3-0.5) | Demand large effect sizes, blinded protocols, or objective correlates before believing a pain claim | | Mood (PHQ-9, HAM-D, BDI) | LARGE (30-50% in mild-mod depression) | Same — mild antidepressants barely beat placebo; the effect size on YOUR mood is meaningfully smaller than the marketing implies | | Sleep quality (subjective rating) | LARGE | Wearable objective sleep metrics (HRV, deep sleep min) are far harder to placebo | | Fatigue | LARGE | Especially in cancer-related, post-viral, chronic conditions | | Anxiety (subjective) | MODERATE-LARGE | Acute interventions show smaller placebo than chronic | | Sleep latency (objective, polysomnography) | SMALL | Real pharmacology shows up here; subjective sleep quality less so | | Cognitive task performance (Stroop, n-back, RT) | SMALL-MODERATE | Effects often disappear under blinding | | Resting HR, HRV | SMALL | Mostly placebo-immune in healthy subjects | | Blood pressure (objective, ambulatory) | SMALL | Placebo-immune in long-term studies | | Body weight, body composition | SMALL | Placebo-immune; demand DEXA or consistent scale data | | Lipid panel, HbA1c, fasting glucose | NEGLIGIBLE | Placebo-immune | | Hormone panels (testosterone, cortisol, IGF-1) | NEGLIGIBLE | Placebo-immune | | Athletic performance (time trials, 1RM) | SMALL-MODERATE | Caffeine-style ergogenic effects show up vs placebo cleanly | | Mortality, MI, stroke, cancer | ZERO | Placebo cannot save your life. Hard endpoints are placebo-immune. | The single most useful sentence in this entire entry: if a compound's only evidence is "users report" or "I feel sharper" without objective biomarker correlation or placebo-controlled blinded trial data, its effect is at most equal to the placebo magnitude for the relevant endpoint — and often is the placebo magnitude. That doesn't mean it's worthless (real benefit at the placebo magnitude is still real benefit), but it does mean the molecule is not the active ingredient. The ritual is the active ingredient.
▸ Subjective experience (deep)
(Not applicable in the conventional sense — placebo is by definition the subjective experience attributed to an inert intervention. But the meta-experience of recognizing placebo in your own self-experimentation is worth describing.)
The signature of a placebo-dominated response in your own n=1 testing:
- Onset is fast. Effects appear within hours to a few days of starting. Real pharmacology often (not always) takes longer to build.
- Effect is global / generalized. "I feel better, sharper, more focused, mood-lifted, sleeping better, stronger" is unlikely to all be one compound. Placebo halo effect.
- Effect tracks your expectations. If you read a hype thread before dosing, the next session is stronger. If you're skeptical, you feel less. Real pharmacology is more state-independent.
- Effect fades with novelty. Weeks 1-2 strong, weeks 3-4 fading, week 6 "did this ever do anything?" — classic placebo decay curve as ritual normalizes.
- Effect is bigger after a purchase decision or social commitment. You posted about it on Discord, you bought the premium vendor, you're 4 days into a stack rotation — placebo expectancy is loaded.
- Effect doesn't show up on objective measurement. HRV, sleep efficiency from a ring, blood pressure, lipid panel, grip strength dynamometer — flat.
When you see this pattern, the responsible interpretation is "this might be working, but the placebo cloud is large enough that I can't tell." The fix is some combination of: longer washout periods, blinded N=1 protocols (encapsulated unmarked doses with a partner randomizing), objective biomarker tracking, and prior commitment to a specific endpoint before measuring.
▸ Tolerance + cycling deep dive
- Placebo decay over time. Yes — the effect fades as ritual becomes routine and novelty / expectancy attenuates. Most pronounced in subjective endpoints over 4-12 weeks.
- Reset via novelty. Switching brand, reformulating ritual, changing dose schedule, restarting after a break — all amplify placebo response. This is why "rotating stacks" feels effective beyond the pharmacological story.
- No physiological tolerance. There is no receptor downregulation to a placebo. Tolerance is purely cognitive / motivational.
▸ Stacking deep dive
Synergistic with (in the placebo-amplification sense — to be aware of, not to use)
- Confidence cues. Premium vendor branding, professional packaging, expensive price points, third-party COA verification — all amplify expectancy.
- Social context. Discord communities, podcaster endorsement, peer-group adoption, "expert" framing.
- Ritual complexity. Multi-step daily protocols (8 AM dose, breakfast pairing, fasted state, tracked log) generate more placebo than single-pill regimens.
- Investment cost. Both monetary and time-investment correlate with effect magnitude.
Avoid (if you want to minimize placebo cloud in your N=1)
- Hype-thread reading immediately before dosing.
- Stack stacking (running 5+ compounds simultaneously, none of which you've ever tested in isolation) — placebo halo across the whole stack.
- Self-reporting in a community where you've already publicly committed to the compound.
Neutral / safe co-administration
- All actual compounds. Placebo doesn't pharmacologically interact with anything. The interaction is conceptual: every compound's effect size is a sum of pharmacology + placebo, and the relevant question is the ratio.
▸ Drug interactions deep dive
Not applicable in the pharmacological sense. Conceptually, the placebo response is the baseline against which all drug effects are measured — drug efficacy is by definition the (drug + placebo) effect minus the (placebo alone) effect.
▸ Pharmacogenomics
Emerging field. Some signals:
- COMT Val158Met polymorphism — Val/Val (low COMT) homozygotes show smaller placebo responses in IBS (Hall 2012) and other conditions. Mechanism: prefrontal dopamine clearance differences affect expectancy circuits.
- Opioid receptor polymorphisms (OPRM1) — variants associated with differential response to placebo analgesia.
- Dopamine receptor polymorphisms (DRD2, DRD3) — Parkinson's placebo response variability tracked to DRD3 variants.
Practical implication: minimal — there is no actionable "placebo phenotype" test, and the gene effects are small and contested. Worth knowing the field exists, but not worth ordering a panel for.
▸ Sourcing deep dive
Not applicable. Placebos are not a product to source. Active placebos (intentionally inert substances used as comparators in trials) are sourced by trial sponsors — typically lactose, microcrystalline cellulose, starch, sucrose, saline solution, or empty capsule shells. The historical "active placebos" (atropine, niacin, alcohol — chosen to mimic side effects) are no longer ethically standard.
For self-experimenters who want to run blinded N=1 protocols at home, gelatin capsules + filler (rice flour, microcrystalline cellulose) packed by a partner is the standard approach. Capsule sizes 00 or 0 are large enough to hide most powdered compounds. The harder problem is matching color and flavor of compounds with distinct organoleptic signatures (e.g., choline-containing compounds have a fishy aftertaste that breaks blinding).
▸ Biomarkers to track (deep)
(Reverse framework — biomarkers ranked by placebo immunity.)
Most placebo-resistant (high signal-to-noise for real pharmacology):
- Mortality, MI, stroke, fracture incidence, cancer recurrence (years-long endpoints in large RCTs)
- Lab biomarkers — lipid panel, HbA1c, fasting insulin, hsCRP, ferritin, TSH, sex hormones
- Body composition by DEXA
- Polysomnography sleep architecture (REM%, deep sleep min)
- 5K time, 1RM, Wingate power output (with proper testing protocol)
- Cognitive task performance under blinded conditions
Moderately placebo-resistant:
- Wearable HR / HRV / sleep efficiency (placebo signal exists but is small)
- Weekly weigh-in / body-fat caliper trends
- Grip strength dynamometer
- VO2max measured
Placebo-permeable (use with care):
- Symptom diaries (mood, energy, libido, anxiety)
- Sleep quality self-rating
- Pain VAS
- Stroop / n-back / Quantified Mind apps without blinding
- "How clear-headed do you feel today" 1-10 scales
Pure placebo signal (unreliable):
- Single-day before/after subjective comparison
- Reports posted to social media within days of starting
- "I just feel different" without measurement
- Brand-loyalty-driven comparisons across vendors
▸ Controversies / open debates Live debate
Is the placebo effect "real" or methodological artifact? Hróbjartsson & Gøtzsche's central claim: most apparent placebo effect in RCTs is regression to the mean + natural history of the disease + patient-reporting bias, not a true biological response to the placebo intervention. Counter-claim: open-label placebo trials, neuroimaging signatures, and naloxone-reversal of placebo analgesia demonstrate real biological response. Modern consensus: both are partly right. Some of what's labeled "placebo effect" in observational studies is regression / natural history. Some is genuine expectancy / conditioning / ritual-driven biology. The two contribute differentially across endpoints.
Open-label placebo replicability outside IBS. Kaptchuk's IBS results have replicated in chronic low back pain, cancer fatigue, ADHD, allergic rhinitis, and migraine — but each replication is small (N<100 typically), and the field is still establishing whether open-label placebo works for most chronic-symptom conditions or just a subset. Skeptics argue the effect sizes shrink dramatically with rigorous methodology and longer follow-up.
Active placebo in antidepressant trials. Moncrieff & Kirsch's analysis suggests that "antidepressants barely beat placebo" because the placebo arm is functionally unblinded by absence of side effects. If patients in the placebo arm correctly guess they're on placebo and patients in the drug arm correctly guess they're on drug, then "expectancy" is asymmetric and inflates the apparent drug-vs-placebo difference. Active-placebo trials (using atropine to mimic side effects in the placebo arm) show much smaller drug-vs-placebo differences. Industry-funded researchers contest this; the methodological point is real.
Ethics of placebo prescription. Surveys show 30-50% of clinicians admit to occasionally prescribing "deceptive placebos" (sugar pills, vitamins framed as treatments) for patients with somatic symptom disorders, fibromyalgia, IBS, or low back pain. This is ethically contested. Open-label placebo (Kaptchuk's framework) sidesteps the deception problem but is not yet standard of care.
Why nootropic communities massively overestimate compound effects. Three converging mechanisms: (a) no blinding — every user knows what they're taking, expectancy is loaded; (b) retrospective justification — users committed financial and identity capital to a stack, downregulating reports of "didn't work" via cognitive dissonance reduction; (c) social-context-induced effects — community reinforcement amplifies the experienced effect through both expectancy and reporting bias. The result: a compound with true pharmacological effect size of 0.1 reads as a "life-changing" effect in community reports. This is the single biggest reason to apply heavy skepticism to non-RCT nootropic evidence.
The "placebo response is increasing over time" debate. Tuttle et al. (2015) and others reported that placebo response in pain trials has grown over decades, possibly explaining why many analgesic drugs that previously beat placebo now fail. Mechanism unclear: rising direct-to-consumer advertising, greater patient health literacy, larger trials with more elaborate protocols, regression artifact? Open question.
▸ Verdict change log
- 2026-05-10 — Initial verdict: REFERENCE-ENTRY. Confidence HIGH. This is a structural / educational entry, not a compound recommendation. Verdict will not change — the placebo phenomenon is well-established and the entry is meant to be evergreen calibration material for readers interpreting every other Nootpedia entry.
▸ Open questions / gaps Open
What's YOUR personal placebo magnitude? Highly individual and context-dependent. Some self-experimenters run remarkably "placebo-immune" (low expectancy, high analytical skepticism) — they consistently report null effects from interventions that produce strong placebo signals in others. Others are highly placebo-responsive. Useful to know your own pattern, even though there's no validated test.
How much of "X compound works for me" is the molecule vs the ritual? Answerable only with blinded N=1 self-experimentation. Most users will never bother. The honest framing: assume placebo accounts for 30-70% of any subjective benefit you report from a non-RCT-validated compound.
What's the right placebo-control strategy for self-experiments? No standard. Suggested approach: encapsulated unmarked doses + partner-randomized administration + objective endpoint + 6+ week protocol + post-hoc unblinding. Almost no one does this.
Are some compound classes more "placebo-amplified" than others? Yes — adaptogens, nootropic herbs, "feel-good" neutraceuticals (5-HTP, GABA, ashwagandha) tend to have larger placebo : pharmacology ratios than well-characterized stimulants (caffeine, modafinil) or hard-endpoint pharmaceuticals (statins, antidiabetics). The ratio is roughly: subjective-endpoint compounds with diffuse mechanisms → placebo-dominated; objective-endpoint compounds with specific receptor targets → pharmacology-dominated.
Open-label placebo for stack rotation. Could biohackers benefit from intentional open-label placebo cycling — taking known sugar pills with explicit awareness, leveraging the conditioning of past compound use? Speculative, untested, mechanism-plausible. Would be the most honest version of "stack rotation."
References
Beecher 1955 — The Powerful Placebo (JAMA)
PMID 13271123. Historical anchor; methodologically flawed but field-defining.
View StudyLevine, Gordon & Fields 1978 — The mechanism of placebo analgesia (Lancet)
PMID 80248. Original naloxone-reversibility demonstration.
View StudyAmanzio & Benedetti 1999 — Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems (J Neurosci)
PMID 9920691. Mechanism dissection.
View Studyde la Fuente-Fernández et al. 2001 — Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease (Science)
PMID 11498597. Real dopamine release from sham levodopa.
View StudyZubieta et al. 2005 — Placebo effects mediated by endogenous opioid activity on mu-opioid receptors (J Neurosci)
PMID 16093383. PET imaging of placebo opioid release.
View StudyCarvalho et al. 2016 — Open-label placebo treatment in chronic low back pain (PAIN)
PMID 27755279. Replication of open-label placebo.
View StudyMoncrieff & Kirsch 2005 — Efficacy of antidepressants in adults (BMJ)
Active-placebo controversy.
View StudyWaber et al. 2008 — Commercial features of placebo and therapeutic efficacy (JAMA)
Price-of-placebo effect.
View StudyCharlesworth et al. 2017 — Effects of placebos without deception compared with no treatment: A systematic review and meta-analysis (J Evid Based Med)
PMID 28452193. Open-label vs deceptive meta-analysis.
View StudyHall, Loscalzo & Kaptchuk 2015 — Genetics and the placebo effect: the placebome (Trends Mol Med)
PMID 25883069. Placebo pharmacogenomics review.
View StudyAder & Cohen 1975 — Behaviorally conditioned immunosuppression (Psychosom Med)
PMID 1162023. Foundational conditioning evidence.
View StudyKaptchuk et al. 2010 — Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome (PLoS ONE)
PMID 21203519. Foundational open-label placebo paper.
View SourceHróbjartsson & Gøtzsche 2010 — Placebo interventions for all clinical conditions (Cochrane Database Syst Rev)
PMID 20091554. The most comprehensive systematic review of placebo magnitude across conditions and endpoint types.
View SourceWager et al. 2015 — An fMRI-Based Neurologic Signature of Placebo Analgesia (PAIN)
PMID 25789440. Neuroimaging evidence for distinct placebo brain signature.
View SourceWood et al. 2020 — N-of-1 Trial of a Statin, Placebo, or No Treatment (NEJM)
Statin nocebo demonstration.
View SourceLatest research
- mechanismAn fMRI-Based Neurologic Signature of Placebo Analgesia (Wager et al., PAIN)Multi-study fMRI data identifies a neurologic signature distinguishing placebo-induced from drug-induced analgesia. Placebo analgesia engages prefrontal regulatory regions (dorsolateral PFC, anterior cingulate) that gate descending pain modulation through the periaqueductal gray; the signature is detectable but distinct from the pharmacological pain-blocker signature.
- trialPlacebos without Deception — A Randomized Controlled Trial in Irritable Bowel Syndrome (Kaptchuk et al., PLoS ONE)Open-label placebo (patients explicitly told they were getting an inert pill, twice daily, with full disclosure of placebo mechanism) outperformed no-treatment in IBS symptom relief at 3 weeks. Shattered the "deception is required" assumption.
- systematic-reviewPlacebo interventions for all clinical conditions (Hróbjartsson & Gøtzsche, Cochrane Database Syst Rev)234 trials, 60 conditions. Placebo had no important effect on most binary or objective endpoints, but produced consistent moderate effects on patient-reported continuous outcomes — pain in particular. Effect grows with patient expectations and trial-design features (informed consent emphasizing placebo possibility, novel intervention, etc.).
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.